New drug discovery strategies for the treatment of benznidazole-resistance in , the causative agent of Chagas disease.

Introduction: Benznidazole, the drug of choice for treating Chagas Disease (CD), has significant limitations, such as poor cure efficacy, mainly in the chronic phase of CD, association with side effects, and parasite resistance. Understanding parasite resistance to benznidazole is crucial for developing new drugs to treat CD.

Areas Covered: Here, the authors review the current understanding of the molecular basis of benznidazole resistance.